Effect of particle size on oral bioavailability of darunavir-loaded solid lipid nanoparticles

References

• Aji Alex MR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci, 2011;42:11–8.
   PubMed Web of Science ®Google Scholar
• Awaad A, Nakamura M, Ishimura K. Imaging of size-dependent uptake and identification of novel pathways in mouse Peyer’s patches using fluorescent organosilica particles. Nanomedicine, 2012;8:627–36.
   PubMed Web of Science ®Google Scholar
• Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet, 2000;356:1423–30.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Shukla D, Mishra B, Singh S. Lipid-an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm, 2009;73:1–15.
   PubMed Web of Science ®Google Scholar
• Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech, 2011;12:62–76.
   PubMed Web of Science ®Google Scholar
• de Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wigerinck P, de Bethune MP. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother, 2005;49:2314–21.
   PubMed Web of Science ®Google Scholar
• Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: Effect of particle size. Pharm Res, 1996;13:1838–45.
   PubMed Web of Science ®Google Scholar
• Doktotovova S, Shegokar R, Fernandes L, Martins-lopes P, Silva AM, Muller RH, Souto EB. Trehalose is not a universal solution for solid lipid nanoparticles freeze-drying. Pharm Dev Technol, 2014;19:922–9.
   PubMed Web of Science ®Google Scholar
• Gonçalves L, Maestrelli F, Mannelli L, Ghelardini C, Almeida A, Mura P. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide. Eur J Pharm Biopharm, 2016;102:41–50.
   PubMed Web of Science ®Google Scholar
• Haubrich R, Berger D, Chilliade P, Colson A, Conant M, Gallant J, Wilkin T, Nadler J, Pierone G, Saag M, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. Aids, 2007;21:F11–18.
   PubMed Web of Science ®Google Scholar
• He C, Yin L, Tang C. Yin Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs. Biomaterials, 2012;33:8569–78.
   PubMed Web of Science ®Google Scholar
• ICH Guidelines Q1A(R2). Stability testing of new drug substances and products: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. 2003.
   Google Scholar
• Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems – An overview. Acta Pharm Sin B, 2013;3:361–72.
   Web of Science ®Google Scholar
• Kovacevic A, Savic S, Vuleta G, Muller RH, Keck CM. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): Effects on size, physical stability and particle matrix structure. Int J Pharm, 2011;406:163–72.
   PubMed Web of Science ®Google Scholar
• Kwon HY, Lee JY, Choi SW, Jang Y, Kim JH. Preparation of PLGA nanoparticles containing oestrogen by emulsification-diffusion method. Colloids Surf A Physicochem Eng Asp, 2001;182:123–30.
   Web of Science ®Google Scholar
• Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: Profile of darunavir. AIDS Rev, 2008;10:131.
   PubMed Web of Science ®Google Scholar
• McKeage K, Perry CM, Keam SJ. Darunavir: A review of its use in the management of HIV infection in adults. Drugs, 2009;69:477–503.
   PubMed Web of Science ®Google Scholar
• Menéndez-Arias L. Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments. Antiviral Res, 2013;98:93–120.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Ray S, Thakur R. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci, 2009;71:349.
   PubMed Web of Science ®Google Scholar
• Neves AR, Lucio M, Martins S, Lima JL, Reis S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine, 2013;8:177–87.
   PubMed Web of Science ®Google Scholar
• PREZISTA. 2006. Prezista-Scientific discussion [Online]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000707/WC500041754.pdf. Accessed April 2015.
   Google Scholar
• Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. Aids, 1999;13:2061–8.
   PubMed Web of Science ®Google Scholar
• Ramasamy T, Tran TH, Choi JY, Cho HJ, Kim JH, Yong CS, Choi HG, Kim JO. Layer-by-layer coated lipid-polymer hybrid nanoparticles designed for use in anticancer drug delivery. Carbohydr Polym, 2014;102:653–61.
   PubMed Web of Science ®Google Scholar
• Rittweger M. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet, 2007;46:739–56.
   PubMed Web of Science ®Google Scholar
• Sosnik A, Chiappetta DA, Carcaboso AM. Drug delivery systems in HIV pharmacotherapy: What has been done and the challenges standing ahead. J Control Release, 2009;138:2–15.
   PubMed Web of Science ®Google Scholar
• Tenore S, Ferreira P. The place of protease inhibitors in antiretroviral treatment. Braz J Infect Dis, 2009;13:371–4.
   PubMed Web of Science ®Google Scholar
• Thommes M, Baert L, van’t Klooster G, Geldof M, Schueller L, Rosier J, Kleinebudde P. Improved bioavailability of darunavir by use of κ-carrageenan versus microcrystalline cellulose as pelletisation aid. Eur J Pharm Biopharm, 2009;72:614–20.
   PubMed Web of Science ®Google Scholar
• van Winden ECA, Crommelin DJA. Long term stability of freeze-dried, lyoprotected doxorubicin liposomes. Eur J Pharm Biopharm, 1997;43:295–307.
   Web of Science ®Google Scholar
• Vitorino C, Carvalho FA, Almeida AJ, Sousa JJ, Pais AA. The size of solid lipid nanoparticles: An interpretation from experimental design. Colloids Surf B Biointerfaces, 2011;84:117–30.
   PubMed Web of Science ®Google Scholar
• Wagner D, Spahn-Langguth H, Hanafy A, Koggel A, Langguth P. Intestinal drug efflux: Formulation and food effects. Adv Drug Deliv Rev, 2001;50:S13–31.
   PubMed Web of Science ®Google Scholar
• Yang D, Hrymak AN. Crystal Morphology of hydrogenated castor oil in the crystallization of oil-in-water emulsions: Part I. Effect of temperature. Ind Eng Chem Res, 2011;50:11585–93.
   Web of Science ®Google Scholar